{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oropharyngeal+Carcinoma", "query": { "condition": "Oropharyngeal Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 586, "total_pages": 59, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oropharyngeal+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T08:02:57.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HNSCC", "Lip SCC", "Oral Cavity Cancer", "Oropharynx Cancer", "Larynx Cancer", "Hypopharynx Cancer", "Nasopharynx Cancer", "Sinonasal Carcinoma", "Cutaneous Squamous Cell Carcinoma", "Head and Neck Neoplasms", "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab, Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2017-03-28", "completion_date": "2025-09-11", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03082534" }, { "nct_id": "NCT01844557", "title": "Testing Accountability in Patient Adherence", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head And Neck Cancer" ], "interventions": [ { "name": "Swallowing Exercises", "type": "OTHER" }, { "name": "Symptom Inventory", "type": "BEHAVIORAL" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2013-05", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844557" }, { "nct_id": "NCT02178072", "title": "Window Trial 5-aza in HNSCC, T-tare", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "5-Azacitadine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 18, "start_date": "2015-02-19", "completion_date": "2019-10-23", "has_results": false, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178072" }, { "nct_id": "NCT01365169", "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Head and Neck Neoplasm", "Malignant Neoplasm", "Metastatic Malignant Neoplasm in the Neck", "Metastatic Malignant Neoplasm in the Uterine Cervix", "Pancreatic Adenocarcinoma", "Pancreatic Neuroendocrine Carcinoma", "Recurrent Colorectal Carcinoma", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Hypopharyngeal Carcinoma AJCC v7", "Stage I Major Salivary Gland Cancer AJCC v7", "Stage I Nasopharyngeal Carcinoma AJCC v7", "Stage I Oral Cavity Cancer AJCC v6 and v7", "Stage I Oropharyngeal Carcinoma AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7", "Stage II Major Salivary Gland Cancer AJCC v7", "Stage II Nasopharyngeal Carcinoma AJCC v7", "Stage II Oral Cavity Cancer AJCC v6 and v7", "Stage II Oropharyngeal Carcinoma AJCC v6 and v7", "Stage IIA Colorectal Cancer AJCC v7", "Stage IIB Colorectal Cancer AJCC v7", "Stage IIC Colorectal Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Hypopharyngeal Carcinoma AJCC v7", "Stage III Laryngeal Cancer AJCC v6 and v7", "Stage III Major Salivary Gland Cancer AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Oral Cavity Cancer AJCC v6 and v7", "Stage III Oropharyngeal Carcinoma AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Hypopharyngeal Carcinoma AJCC v7", "Stage IVA Laryngeal Cancer AJCC v7", "Stage IVA Major Salivary Gland Cancer AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVA Oropharyngeal Carcinoma AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Hypopharyngeal Carcinoma AJCC v7", "Stage IVB Laryngeal Cancer AJCC v7", "Stage IVB Major Salivary Gland Cancer AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oropharyngeal Carcinoma AJCC v7", "Metastatic or Locally Unresectable Solid Tumor" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Health Telemonitoring", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2011-05-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365169" }, { "nct_id": "NCT00049166", "title": "Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage II Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2002-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049166" }, { "nct_id": "NCT04106362", "title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "KRAS Protein Variant", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-01-14", "completion_date": "2023-05-23", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106362" }, { "nct_id": "NCT02917629", "title": "ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Cavity Neoplasm", "Oropharyngeal Neoplasm", "Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7", "Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-05-31", "completion_date": "2019-08-28", "has_results": true, "last_update_posted_date": "2023-03-08", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Minneapolis, Minnesota • Rochester, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "New York" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02917629" }, { "nct_id": "NCT06702033", "title": "The Minimalist Trial-2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-Related Oropharynx Squamous Cell Carcinoma" ], "interventions": [ { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2025-04-10", "completion_date": "2033-07-15", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 3, "location_summary": "St Louis, Missouri • Fargo, North Dakota • Sioux Falls, South Dakota", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06702033" }, { "nct_id": "NCT04588038", "title": "NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Resectable Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Efineptakin alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hyunseok Kang, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-03-12", "completion_date": "2025-02-03", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04588038" }, { "nct_id": "NCT04667585", "title": "Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oropharynx Cancer" ], "interventions": [ { "name": "De-escalated radiation dose", "type": "RADIATION" }, { "name": "Standard radiation dose", "type": "RADIATION" }, { "name": "18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2021-04-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-06-10T08:02:57.498Z", "location_count": 2, "location_summary": "Durham, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04667585" } ] }